IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017
$47,755,723
| Recipient | BIOCRYST PHARMACEUTICALS INC UEI MGXADJ6SCLJ5 |
|---|---|
| Award ID | HHSN272201300017C |
| Award amount | $47,755,723 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY |
| PSC | AN11 |
| Start date | Sep 16, 2013 |
| End date | Sep 30, 2022 |
| Place of performance | DURHAM, NC |
| Record updated | Sep 6, 2024 |
View the official award record
More awards won by BIOCRYST PHARMACEUTICALS INC
BPA FOR ORLADEYO AND RAPIVAB
Department of Veterans Affairs · $93,000,000 · Jun 3, 2026
PERAMIVIR, RAPIVAB FLU TREATMENT
Department of Health and Human Services · $34,660,000 · Sep 1, 2018
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))
Department of Health and Human Services · $13,877,674 · Sep 30, 2024
COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.
Department of Health and Human Services · $6,326,480 · Sep 1, 2020
BULK ORLADEYO PHARMACEUTICAL
Department of Veterans Affairs · $394,853 · Mar 12, 2025
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids